NEW YORK A federal judge on Thursday scheduled a trial for June 2017 in the U.S. government's securities fraud case against former pharmaceutical executive Martin Shkreli, who became a lightning rod last year for outrage over soaring prescription drug prices.
U.S. District Judge Kiyo Matsumoto, in Brooklyn, New York, set a June 26, 2017, trial date in the case against Shkreli and Evan Greebel, a former lawyer for Retrophin Inc (RTRX.O), a biopharmaceutical company which Shkreli headed until 2014.
(Reporting by Nate Raymond in New York; Editing by Leslie Adler)
This story has not been edited by Firstpost staff and is generated by auto-feed.
Published Date: Jul 15, 2016 00:30 AM | Updated Date: Jul 15, 2016 00:30 AM